Hazard of the Sakel treatment in insulin potentiation by means of ganglionic-blocking agents of the methonium group and tolbutamide.
D003295:Convulsive Therapy / Q000009:adverse effects*; D006584:Hexamethonium Compounds / Q000009:adverse effects*; D006801:Humans; D012559:Schizophrenia / Q000628:therapy*; D014044:Tolbutamide / Q000009:adverse effects*
D006584:Hexamethonium Compounds; D014044:Tolbutamide